David Turkaly
Stock Analyst at Citizens
(2.29)
# 2,761
Out of 5,090 analysts
143
Total ratings
43.51%
Success rate
-2.79%
Average return
Main Sectors:
Stocks Rated by David Turkaly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TELA TELA Bio | Maintains: Market Outperform | $7 → $5 | $1.15 | +334.78% | 7 | Nov 14, 2025 | |
| APYX Apyx Medical | Upgrades: Market Outperform | $8 | $3.94 | +103.05% | 6 | Nov 12, 2025 | |
| AXGN Axogen | Maintains: Market Outperform | $26 → $34 | $33.32 | +2.04% | 8 | Oct 30, 2025 | |
| KIDS OrthoPediatrics | Maintains: Market Outperform | $35 → $25 | $18.42 | +35.72% | 12 | Oct 10, 2025 | |
| LNTH Lantheus Holdings | Maintains: Market Outperform | $112 → $73 | $63.30 | +15.32% | 9 | Aug 7, 2025 | |
| OFIX Orthofix Medical | Reiterates: Market Perform | n/a | $15.90 | - | 2 | Jun 6, 2025 | |
| GMED Globus Medical | Reiterates: Market Perform | n/a | $91.10 | - | 3 | May 27, 2025 | |
| HAE Haemonetics | Reiterates: Market Outperform | $100 | $83.94 | +19.13% | 12 | May 20, 2025 | |
| STE STERIS | Maintains: Market Outperform | $265 → $280 | $263.28 | +6.35% | 18 | May 16, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Market Outperform | $35 → $25 | $13.23 | +88.96% | 15 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $62 → $55 | $27.02 | +103.55% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $140 → $125 | $94.28 | +32.58% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $400 → $500 | $512.03 | -2.35% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $364.02 | - | 3 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $120.50 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $32 | $19.68 | +62.60% | 7 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $16 | $7.91 | +102.28% | 1 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $3 | $1.35 | +122.22% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $8.65 | -42.20% | 1 | Oct 6, 2017 |
TELA Bio
Nov 14, 2025
Maintains: Market Outperform
Price Target: $7 → $5
Current: $1.15
Upside: +334.78%
Apyx Medical
Nov 12, 2025
Upgrades: Market Outperform
Price Target: $8
Current: $3.94
Upside: +103.05%
Axogen
Oct 30, 2025
Maintains: Market Outperform
Price Target: $26 → $34
Current: $33.32
Upside: +2.04%
OrthoPediatrics
Oct 10, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $18.42
Upside: +35.72%
Lantheus Holdings
Aug 7, 2025
Maintains: Market Outperform
Price Target: $112 → $73
Current: $63.30
Upside: +15.32%
Orthofix Medical
Jun 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $15.90
Upside: -
Globus Medical
May 27, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $91.10
Upside: -
Haemonetics
May 20, 2025
Reiterates: Market Outperform
Price Target: $100
Current: $83.94
Upside: +19.13%
STERIS
May 16, 2025
Maintains: Market Outperform
Price Target: $265 → $280
Current: $263.28
Upside: +6.35%
Integra LifeSciences Holdings
May 9, 2025
Maintains: Market Outperform
Price Target: $35 → $25
Current: $13.23
Upside: +88.96%
May 9, 2025
Maintains: Market Outperform
Price Target: $62 → $55
Current: $27.02
Upside: +103.55%
May 7, 2025
Maintains: Market Outperform
Price Target: $140 → $125
Current: $94.28
Upside: +32.58%
May 5, 2025
Maintains: Market Outperform
Price Target: $400 → $500
Current: $512.03
Upside: -2.35%
May 5, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $364.02
Upside: -
Apr 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $120.50
Upside: -
Feb 25, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $19.68
Upside: +62.60%
Jan 29, 2025
Reiterates: Market Outperform
Price Target: $16
Current: $7.91
Upside: +102.28%
Aug 14, 2024
Maintains: Market Outperform
Price Target: $7 → $3
Current: $1.35
Upside: +122.22%
Oct 6, 2017
Initiates: Outperform
Price Target: $5
Current: $8.65
Upside: -42.20%